This trial offers significant advantages over previous efforts to determine effective treatments for NSSI.
It should be noted that this trial offers meticulous eye examinations for glaucoma screening but not actual treatment and care.
By combining clinical effectiveness data with an economic evaluation and with direct information from primary stakeholders, this trial offers a complete and thorough view on ST as a contribution to the improvement of treatment for this PD patient group.
This trial offers a unique opportunity to identify effective ways of providing feedback to parents about their child's weight status and to assess the efficacy of a supportive, individualised early intervention to improve weight outcomes in young children.
While this trial offers the ability to examine AR as a therapeutic tool, data on attentional bias and its relation to urges to smoke, cue-induced cravings and resumption of smoking will enhance our understanding of relapse and possible preventative strategies.
The fact that most patients believed the trial offered the best treatment perhaps allows them to feel more altruistic, this was true for those offered adjuvant or palliative trial treatments.
Nonetheless, the trial offered an alternative to cisplatin-based treatment with a novel delivery time.
Only five minutes left for this trial offer.
This clinical trial offered the opportunity to objectify the impact of an AMPA receptor blockade on the visual system by psychophysical and electrophysiological means in vivo.
